Recommendations regarding the response assessment in CLL patients
| Diagnostic test . | Section of guidelines . | General practice . | Clinical trial . |
|---|---|---|---|
| History, physical examination | 5.1.2, 5.1.3, 5.1.4, 5.2.2, 5.2.3, 5.3.1, 5.3.2 | Always | Always |
| CBC and differential count | 5.1.1, 5.1.5, 5.2.4, 5.3.3, 5.3.5 | Always | Always |
| Marrow aspirate and biopsy | 5.1.6 | At cytopenia of uncertain cause | At CR or cytopenia of uncertain cause |
| Assessment for minimal residual disease | 5.9 | NGI | Desirable |
| Ultrasound of the abdomen* | 5.1.2, 5.1.3, 5.2.2, 5.2.3, 5.3.1, 5.3.2 | Possible, if previously abnormal | NGI |
| CT scans of chest, pelvis, and abdomen | 5.1.2, 5.1.3, 5.2.2, 5.2.3, 5.3.1, 5.3.2 | NGI | Recommended if previously abnormal and otherwise with a CR |
| Diagnostic test . | Section of guidelines . | General practice . | Clinical trial . |
|---|---|---|---|
| History, physical examination | 5.1.2, 5.1.3, 5.1.4, 5.2.2, 5.2.3, 5.3.1, 5.3.2 | Always | Always |
| CBC and differential count | 5.1.1, 5.1.5, 5.2.4, 5.3.3, 5.3.5 | Always | Always |
| Marrow aspirate and biopsy | 5.1.6 | At cytopenia of uncertain cause | At CR or cytopenia of uncertain cause |
| Assessment for minimal residual disease | 5.9 | NGI | Desirable |
| Ultrasound of the abdomen* | 5.1.2, 5.1.3, 5.2.2, 5.2.3, 5.3.1, 5.3.2 | Possible, if previously abnormal | NGI |
| CT scans of chest, pelvis, and abdomen | 5.1.2, 5.1.3, 5.2.2, 5.2.3, 5.3.1, 5.3.2 | NGI | Recommended if previously abnormal and otherwise with a CR |
General practice is defined as the use of accepted treatment options for a patient with CLL who is not enrolled in a clinical trial.
NGI indicates not generally indicated.
Used in some countries to monitor lymphadenopathy and organomegaly.